학술논문
Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study
Document Type
Article
Author
Source
In: Clinical Infectious Diseases . (Clinical Infectious Diseases, 1 September 2023, 77(5):740-748)
Subject
Language
English
ISSN
15376591
10584838
10584838